Adel Boutros, MD
Family Medicine · Lake Forest, CANPI 1700952827
Payments from drug & device makers
Across 147 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$366
- Vanda Pharmaceuticals Inc.$327
- Lilly USA, LLC$202
- Sunovion Pharmaceuticals Inc.$171
- Astellas Pharma US Inc$161
- Teva Pharmaceuticals USA, Inc.$139
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,081100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $366 |
| Vanda Pharmaceuticals Inc. | 12 | $327 |
| Lilly USA, LLC | 10 | $202 |
| Sunovion Pharmaceuticals Inc. | 7 | $171 |
| Astellas Pharma US Inc | 9 | $161 |
| Teva Pharmaceuticals USA, Inc. | 6 | $139 |
| GSK | 6 | $133 |
| Bayer | 6 | $126 |
| Neurocrine Biosciences, Inc. | 4 | $125 |
| Novartis | 7 | $117 |
| Nestle Healthcare Nutrition Inc. | 4 | $106 |
| Amgen | 5 | $104 |
| Corium, LLC | 3 | $76 |
| Amarin Pharma, Inc. | 4 | $76 |
| Novo Nordisk | 4 | $73 |
| Abbott | 2 | $58 |
| Urovant Sciences Inc | 3 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Acadia Pharmaceuticals Inc | 3 | $49 |
| Sun Pharmaceutical Industries Inc. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Lucid Diagnostics Inc. | 2 | $41 |
| Avanir Pharmaceuticals, Inc. | 2 | $39 |
| Corcept Therapeutics | 1 | $37 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Scilex Pharmaceuticals Inc. | 2 | $37 |
| CMP Pharma, Inc. | 2 | $35 |
| Radius Health, Inc. | 1 | $30 |
| Grifols USA, LLC | 1 | $27 |
| AbbVie | 1 | $24 |
| Tempus AI, Inc | 1 | $23 |
| Mylan Specialty L.p. | 1 | $23 |
| Indivior Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| UCB, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $13 |
How this compares
$3,081 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 108 | $650,994 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 393 | $613,274 |
| Metformin Er GastricMetformin Hcl | 283 | $368,956 |
| JanuviaSitagliptin Phosphate | 523 | $278,223 |
| EliquisApixaban | 371 | $201,291 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 171 | $113,263 |
| Austedo XrDeutetrabenazine | 19 | $107,163 |
| OzempicSemaglutide | 98 | $97,749 |
| JardianceEmpagliflozin | 141 | $86,443 |
| Diclofenac Sodium | 227 | $82,308 |
| XareltoRivaroxaban | 133 | $69,400 |
| Lactulose | 502 | $67,497 |
| MeloxicamMeloxicam, Submicronized | 46 | $65,475 |
| TrulicityDulaglutide | 68 | $59,165 |
| Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag | 35 | $56,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $125 | $650,994108 claims |
| MerckJanuvia | $16 | $278,223523 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $366 | $153,249228 claims |
| Johnson & JohnsonXarelto, Invega Sustenna, Invokana | $15 | $124,540172 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $202 | $112,268114 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $139 | $107,16319 claims |
| Novo NordiskOzempic | $73 | $97,74998 claims |
| AbbVieLinzess | $24 | $54,92592 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $133 | $50,40496 claims |
| Astellas Pharma US IncMyrbetriq | $161 | $41,04290 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $37 | $34,832105 claims |
| NovartisEntresto | $117 | $34,19651 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Lake Forest
- Rizwana MohseniLake Forest$26.7M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.